This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ventas, Inc. is a healthcare real estate investment trust (REIT) that is primarily engaged in acquisition and ownership of senior housing, R&I and healthcare properties, and leasing them to unaffiliated tenants or operating them through independent third-party managers. Ventas offers MOB management, leasing, marketing, facility development and advisory services to well-rated hospitals and health systems throughout the United States through its ownership interest in PMB Real Estate Services LLC and the company’s subsidiary, Lillibridge Healthcare Services, Inc. It also makes secured and non-mortgage loans and other investments relating to senior housing and healthcare properties or operators.
How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Is it Wise to Hold on to Healthpeak (PEAK) Stock for Now?
by Zacks Equity Research
Healthpeak's (PEAK) focus on enhancing its life-science real-estate assets, capital-recycling moves and a solid balance sheet bodes well. Stiff competition from peers and rising interest rates are woes.
Welltower (WELL) Q4 FFO & Revenues Beat, SHO Occupancy Rises
by Zacks Equity Research
Welltower's (WELL) Q4 results gain on better-than-anticipated revenues. The SHO portfolio occupancy improves year over year. The company issues its 2023 outlook.
Ventas' (VTR) Q4 FFO and Revenues Beat, SHOP NOI Increases
by Zacks Equity Research
Ventas' (VTR) Q4 results outshine estimates on better-than-anticipated revenues. The SHOP same-store NOI improves on strong pricing power and occupancy growth. It issues 2023 outlook.
Ventas (VTR) Q4 FFO and Revenues Beat Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 1.39% and 0.15%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Ventas (VTR)
by Zacks Equity Research
Ventas (VTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ventas (VTR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ventas' (VTR) Q4 earnings are likely to have benefited from the occupancy growth in the SHOP segment. However, higher interest rates and a stronger U.S. dollar might have been a spoilsport.
What's in Store for Healthpeak (PEAK) This Earnings Season?
by Zacks Equity Research
High demand for Healthpeak's (PEAK) life-science assets and rising healthcare spending by senior citizens are likely to have aided its Q4 earnings. Interest rate hikes might have been a deterrent.
Omega Healthcare (OHI) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Rent defaults by some of Omega Healthcare's (OHI) operators facing occupancy and elevated staffing cost pressure, and the firm's restructuring moves might have adversely impacted its Q4 earnings.
Is It Wise to Retain Ventas (VTR) Stock in Your Portfolio?
by Zacks Equity Research
A rise in healthcare spending by senior citizens, accretive investments in the R&I business and a solid balance sheet bode well for Ventas (VTR). Meanwhile, stiff competition and higher interest rates are woes.
Welltower (WELL) Q3 FFO Meets, Revenues Top, Same-Store NOI Up
by Zacks Equity Research
Welltower (WELL) reports healthy Q3 results, with the top line growing year over year. The SHO portfolio witnesses improvement in occupancy. WELL's total same-store NOI increases year over year.
Ventas' (VTR) Q3 FFO Meets, Revenues Beat, SHOP NOI Rises
by Zacks Equity Research
Ventas (VTR) reports better-than-anticipated revenues. The SHOP same-store NOI improves on solid demand and pricing power.
Ventas (VTR) Q3 FFO Meet Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 0% and 0.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Four Corners Property Trust (FCPT) Q3 FFO Match Estimates
by Zacks Equity Research
Four Corners Property (FCPT) delivered FFO and revenue surprises of 0% and 4.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vornado (VNO) Q3 FFO and Revenues Beat Estimates
by Zacks Equity Research
Vornado (VNO) delivered FFO and revenue surprises of 9.46% and 5.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in the Offing for Ventas (VTR) This Earnings Season?
by Zacks Equity Research
Ventas' (VTR) Q3 earnings are likely to have benefited from the occupancy growth of its SHOP portfolio. However, elevated expenses and higher interest rates might have been a spoilsport.
Top Stock Reports for Air Products, Southern Copper & Discover Financial
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Air Products and Chemicals, Inc. (APD), Southern Copper Corporation (SCCO) and Discover Financial Services (DFS).
Here's Why You Should Retain Ventas (VTR) in Your Portfolio
by Zacks Equity Research
Rise in healthcare spending by senior citizens, accretive investments in the R&I business and a solid balance sheet will aid Ventas (VTR). Yet, stiff competition and higher interest rates are woes.
Welltower (WELL) Q2 FFO & Revenues Beat, SHOP Occupancy Up
by Zacks Equity Research
Welltower's (WELL) Q2 results outpace estimates with solid top-line growth. The seniors housing operating portfolio occupancy witnesses significant improvements year over year.
Welltower (WELL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Welltower's (WELL) Q2 earnings are likely to have benefited from occupancy gains in the seniors housing operating portfolio. However, higher expenses in the quarter might have been a deterrent.
Ventas' (VTR) Q2 FFO Meets, Revenues Up Y/Y, SHOP NOI Rises
by Zacks Equity Research
Ventas' (VTR) Q2 results display year-over-year top-line growth aided by solid demand and improving pricing power for the senior housing operating portfolio.
Ventas (VTR) Q2 FFO Meet Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 0% and 1.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The Necessity Retail (RTL) Q2 FFO and Revenues Beat Estimates
by Zacks Equity Research
The Necessity Retail (RTL) delivered FFO and revenue surprises of 7.41% and 16.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ventas (VTR) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ventas' (VTR) Q2 earnings are likely to have benefited from the occupancy growth of its SHOP segment. However, earnings dilution in the triple net and office segments might have been a spoilsport.
Is it Wise to Retain Ventas (VTR) Stock in Your Portfolio?
by Zacks Equity Research
Ventas (VTR) is well-positioned to gain from its diverse healthcare real estate portfolio and a healthy balance-sheet position. Yet, tenant concentration risk and interest rate hikes are major woes.